Valneva (VALN) said Monday that France's national public health agency suspended the use of single-dose chikungunya vaccine Ixchiq in persons at least 65 years old after three cases of serious adverse events, including one death.
The company said "causality has not been definitively established" and the suspension will remain in place pending further investigation.
The serious adverse events, which were reported through the country's pharmacovigilance system, involved individuals over 80 years old with comorbidities who received the vaccine, according to the company.
The vaccine is still recommended for use in individuals 18 to 64 years old in France, Valneva said.
Shares of Valneva were down 7.6% in recent trading.
Price: 6.53, Change: -0.54, Percent Change: -7.64
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.